169 related articles for article (PubMed ID: 37945917)
21. The effectiveness of self-directed medical cannabis treatment for pain.
Li X; Vigil JM; Stith SS; Brockelman F; Keeling K; Hall B
Complement Ther Med; 2019 Oct; 46():123-130. PubMed ID: 31519268
[TBL] [Abstract][Full Text] [Related]
22. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
[TBL] [Abstract][Full Text] [Related]
23. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
24. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses.
Lawn W; Freeman TP; Pope RA; Joye A; Harvey L; Hindocha C; Mokrysz C; Moss A; Wall MB; Bloomfield MA; Das RK; Morgan CJ; Nutt DJ; Curran HV
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3537-52. PubMed ID: 27585792
[TBL] [Abstract][Full Text] [Related]
25. Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients.
Ajrawat P; Yang Y; Wasilewski E; Leroux T; Ladha KS; Bhatia A; Singh M; Thaker S; Kapoor M; Furlan AD; Kotra LP; Clarke H
Cannabis Cannabinoid Res; 2024 Feb; 9(1):267-281. PubMed ID: 36342776
[No Abstract] [Full Text] [Related]
26. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
Fernández N; Cappello MG; Quiroga PN
Forensic Sci Int; 2023 Aug; 349():111762. PubMed ID: 37392612
[TBL] [Abstract][Full Text] [Related]
27. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis.
Spindle TR; Martin EL; Grabenauer M; Woodward T; Milburn MA; Vandrey R
J Psychopharmacol; 2021 Jul; 35(7):786-803. PubMed ID: 34049452
[TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study.
Eisenberg E; Ogintz M; Almog S
J Pain Palliat Care Pharmacother; 2014 Sep; 28(3):216-25. PubMed ID: 25118789
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposes.
Morean ME; Lederman IR
Addict Behav; 2019 Jun; 93():233-239. PubMed ID: 30772776
[TBL] [Abstract][Full Text] [Related]
30. Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure.
Colizzi M; McGuire P; Giampietro V; Williams S; Brammer M; Bhattacharyya S
Eur Neuropsychopharmacol; 2018 Jul; 28(7):850-862. PubMed ID: 29935939
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.
S G; Hb S; K L; R T; Bs R; Ps S; F S; Ab O
Mult Scler Relat Disord; 2021 Feb; 48():102708. PubMed ID: 33387864
[TBL] [Abstract][Full Text] [Related]
32. Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis-Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry.
Kawka M; Erridge S; Holvey C; Coomber R; Usmani A; Sajad M; Platt MW; Rucker JJ; Sodergren MH
J Clin Pharmacol; 2021 Dec; 61(12):1545-1554. PubMed ID: 34473850
[TBL] [Abstract][Full Text] [Related]
33. Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies.
Cooper ZD; Abrams DI
Am J Drug Alcohol Abuse; 2019; 45(6):580-595. PubMed ID: 31687845
[No Abstract] [Full Text] [Related]
34. The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
Cannabis Cannabinoid Res; 2024 Feb; 9(1):230-240. PubMed ID: 35881851
[No Abstract] [Full Text] [Related]
35. Medicinal cannabis for the treatment of anxiety disorders.
Berger M; Amminger GP; McGregor IS
Aust J Gen Pract; 2022 Aug; 51(8):586-592. PubMed ID: 35908759
[TBL] [Abstract][Full Text] [Related]
36. Marijuana use among patients with epilepsy at a tertiary care center.
Kerr A; Walston V; Wong VSS; Kellogg M; Ernst L
Epilepsy Behav; 2019 Aug; 97():144-148. PubMed ID: 31252269
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry.
Tait J; Erridge S; Holvey C; Coomber R; Usmani A; Sajad M; Hoare J; Khan S; Weatherall M; Rucker JJ; Platt M; Sodergren MH
Expert Rev Neurother; 2023 Apr; 23(4):413-423. PubMed ID: 37021592
[TBL] [Abstract][Full Text] [Related]
38. Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?
Freeman TP; Morgan CJ; Hindocha C; Schafer G; Das RK; Curran HV
Addiction; 2014 Oct; 109(10):1686-94. PubMed ID: 24894801
[TBL] [Abstract][Full Text] [Related]
39. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
Miller OS; Elder EJ; Jones KJ; Gidal BE
Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
[TBL] [Abstract][Full Text] [Related]
40. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].
Morgan CJ; Schafer G; Freeman TP; Curran HV
Br J Psychiatry; 2010 Oct; 197(4):285-90. PubMed ID: 20884951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
